Clinical Trial Detail

NCT ID NCT03670966
Title 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Fred Hutchinson Cancer Research Center
Indications

acute myeloid leukemia

acute lymphoblastic leukemia

myelodysplastic syndrome

chronic myelomonocytic leukemia

Therapies

BC8-B10 + Cyclophosphamide + Fludarabine

Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus

Age Groups: adult senior

No variant requirements are available.